Abstract: Compounds of the formula ##STR1## wherein X is oxygen or sulfur;R.sub.1 is hydrogen, methyl or ethyl; andR.sub.2 is methyl or ethyl;and non-toxic, physiologically acceptable salts thereof formed with an inorganic or organic base. The compounds as well as their salts are useful as sweetening agents.

Abstract: Pharmaceutical, cosmetic and pesticidal compositions containing a trifluoroacetyl-resorcinol of the formula ##STR1## wherein R.sub.2 and R.sub.4, which may be identical to or different from each other, are each hydrogen or methyl, andR.sub.3 and R.sub.5, which may be identical to or different from each other, are each hydrogen or ethyl.

Abstract: Pharmaceutical compositions for the treatment of diabetic nephropathy containing bromhexine and a method of treating diabetic nephropathy therewith.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is perfluoroalkyl of 1 to 8 carbon atoms or 2,2,3,3-tetrafluoro-cyclobutyl,R.sub.2 and R.sub.4, which may be identical to or different from each other, are each hydrogen, alkyl of 1 to 10 carbon atoms, aliphatic acyl of 2 to 18 carbon atoms, benzoyl, salicyloyl or phenylacetyl, andR.sub.3 and R.sub.5, which may be identical to or different from each other, are each alkyl of 3 to 18 carbon atoms, halogen, nitro, p-toluenesulfonyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclododecyl, methylcyclohexyl, dimethylcyclohexyl, benzyl, methylthio or ##STR2## where R.sub.1, R.sub.2 and R.sub.4 have the meanings previously defined,Q is --CH.sub.2 -- or --S--, andG is R.sub.5, as above defined, orQ is R.sub.3, as above defined, andG is --CH.sub.2 -- or --S--,R.sub.3 may, in addition, also be hydroxyl, methoxy, methyl or cyano, andR.sub.5 may also be methyl, orone of substituents R.sub.3 and R.sub.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is unsubstituted, mono-substituted or di-substituted thiomorpholino, where the substituents are selected from the group consisting of methyl, hydroxymethyl, hydroxyl, phenyl and benzyl;R.sub.2 is hydrogen, methyl or benzyl; andR.sub.3 is hydrogen, halogen, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as antiphlogistics and antithrombotics.

Abstract: Racemic and optically active compounds of the formula ##STR1## wherein R.sub.1 is --COOR.sub.6, where R.sub.6 is hydrogen or alkyl of 1 to 4 carbon atoms; --OCO--R.sub.9, where R.sub.9 is alkyl of 1 to 6 carbon atoms, phenyl (alkyl of 1 to 4 carbon atoms) or phenyl; --Q--CO--NR.sub.7 R.sub.8, where Q is a single bond, oxygen, --NH--, --CH2-- or --CH.sub.2 --NH--, and R.sub.7 and R.sub.8, taken together with the nitrogen, are pyrrolidino, piperidino or morpholino; cyano-phenyl; carboxyl-phenyl; cyano-phenoxy; or carboxyl-phenoxy;R.sub.2 is hydrogen, halogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 2 to 4 carbon atoms, alkenyl of 2 to 4 carbon atoms, amino, nitro or, together with R.sub.1, 3,4-methylenedioxy;R.sub.3 is hydrogen, halogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or, together with R.sub.2 in the ortho-position, --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.n -- where n is an integer from 3 to 5;R.sub.

Abstract: Racemic and optically active compounds of the formulaQ-C.sub.n H.sub.2n -NH-Rwherein Q is ##STR1## where R.sub.1 is hydrogen, halogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, trifluoromethyl or amino,R.sub.2 is hydrogen, halogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms or trifluoromethyl,R.sub.1 and R.sub.2, together with each other, are methylenedioxy or ethylenedioxy, andA is --O--, --CH.sub.2 --CH.sub.2 --, or --NR.sub.3 -- where R.sub.3 is hydrogen or alkyl or 1 to 4 carbon atoms,n is an integer from 2 to 6, inclusive, andR is hydrogen, benzyl or ##STR2## where R.sub.4 is hydrogen, methyl or ethyl,R.sub.5, R.sub.6 and R.sub.7, which may be identical to or different from each other, are each hydrogen, halogen, hydroxymethyl, trifluoromethyl, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, nitro, cyano, --CONHR.sub.3, --CONHOH, --COOR.sub.3, R.sub.8 O--, methylsulfonylmethyl or, when one or two of R.sub.5 through R.sub.

Abstract: 2-[N-(Cyclopropyl-methyl)-N-(2'-chloro-4'-methyl-thienyl-3')-amino]-2-imida zoline and non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds are useful as bradycardiacs.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is alkyl of 3 to 12 carbon atoms; unsaturated aliphatic hydrocarbyl of 3 to 20 carbon atoms comprising 1 to 3 double bonds and/or one triple bond; phenyl(alkyl of 2 to 4 carbon atoms); methylenedioxybenzyl; chlorobenzyl; indan-5-ylmethyl; indan-3-ylmethyl; phenyl(alkenyl of 2 to 4 carbon atoms); cycloalkyl of 5 to 7 carbon atoms; (cycloalkyl of 3 to 10 carbon atoms)methyl; (methylcycloalkyl of 4 to 11 carbon atoms)methyl; morpholino(alkyl of 2 to 3 carbon atoms); pyrrolidino(alkyl of 2 to 3 carbon atoms); piperidino (alkyl of 2 to 3 carbon atoms); 4-methylpiperazino(alkyl of 2 to 3 carbon atoms); or, when R.sub.3 and/or R.sub.4 are methyl or ethyl, also methyl or ethyl;R.sub.2 is hydrogen, methyl or ethyl; andR.sub.3 and R.sub.4 are each hydrogen, methyl or ethyl;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as the salts are useful as anti-ulcerogenics and secretion inhibitors.

Abstract: Novel 5,11-dihydro-6H-pyrido-[2,3-b][1,4]-benzodiazepine-6-ones of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, straight and branched chain, mono and poly unsaturated aliphatic hydrocarbon of 3 to 20 carbon atoms, phenyl alkyl of 1 to 4 alkyl carbon atoms and cinnamyl, R.sub.2 is selected from the group consisting of hydrogen, methyl and ethyl and A is straight or branched chain alkylene of 2 to 5 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having ulcer inhibiting and secretion inhibiting activity and a novel process for their preparation.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, halogen or cyano;R.sub.2 is fluorine, cyano, trifluoromethyl, nitro or alkyl of 1 to 4 carbon atoms;R.sub.3 is alkoxy of 1 to 5 carbon atoms, alkenyloxy of 2 to 5 carbon atoms, aryloxy of 6 to 10 carbon atoms, aralkoxy of 7 to 11 carbon atoms, or --NR.sub.5 R.sub.6, where R.sub.5 and R.sub.6 are each hydrogen, alkyl of 1 to 5 carbon atoms, alkenyl of 2 to 5 carbon atoms, aryl of 6 to 10 carbon atoms or aralkyl of 7 to 11 carbon atoms; andR.sub.4 is cycloalkyl of 3 to 5 carbon atoms or alkyl of 3 to 5 carbon atoms;and non-toxic, pharmacologically acceptable acid addition salt thereof. The compounds as well as the salts are useful as analgesics, uterospasmolytics and antiasthmatics.

Abstract: Compounds of the formula ##STR1## wherein R is 2,6-dichloro-4-hydroxymethyl-phenyl; 2-chloro-4-methyl-5-amino-phenyl; 2,5-dichloro-4-methyl-phenyl; 2-chloro-4-methyl-5-nitro-phenyl; 2,3-dichloro-4-methyl-phenyl; 2-chloro-4-methyl-6-nitro-phenyl; 2-chloro-4-methyl-6-amino-phenyl; 2,4,6-trifluorophenyl; tetrafluoro-phenyl; or 3-bromo-4-fluoro-phenyl; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as hypotensives.

Abstract: Antiviral pharmaceutical compositions containing as the active ingredient a eukaryotic transfer-ribonucleic acid, and a method of treating viral infections therewith.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are hydrogen or substituents of various types;R.sub.4 is hydrogen, alkyl of 1 to 5 carbon atoms, or optionally substituted aralkyl of 7 to 14 carbon atoms;R.sub.5 is a heterocycle;D is alkylene of 1 to 12 carbon atoms; andA is hydrogen or acyl;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as .alpha.- and .beta.-adrenergic receptor blocking agents and antidepressants.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be identical to or different from each other, are each hydrogen, fluorine, chlorine, bromine, methyl, methoxy or trifluoromethyl, provided that one of them is other than hydrogen; andR.sub.4 and R.sub.5, which may be identical to or different from each other, are each hydrogen or methyl;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as bradycardiacs.

Abstract: Compounds of the formula ##STR1## wherein A is alkylene of 1 to 5 carbon atoms;R.sub.1 is amino, tert.butylamino, N-cyclohexyl-N-methyl-amino, dibenzylamino, benzylamino, trimethoxybenzyl-amino, 1-ethyl-2-pyrrolidinylmethylamino, 1-ethyl-3-piperidinyl-amino, 9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl, 1,2,5,6-tetra-hydro-1-pyridyl, 4-benzyl-piperidino, 1,2,3,6,7,8,9,9a-octahydro-4H-pyrazino[1,2-a]-pyrimidine-1(or-8)yl, 3- or 4-hydroxypiperidino, 3-or 4-methoxypiperidino, 1,2,3,4-tetrahydro-2-isoquinolyl, 3-azaspiro[5.5]undecan-3-yl, 4-oxo-piperidino or the ethyleneketal thereof, hexahydro-3-methyl-1-pyrimidinyl, thiomorpholino, 1-oxido-thiomorpholino, hexahydro-4-methyl-1H-1,4-diazepin-1-yl, 2,6-dimethyl-morpholino,1,4-diazabicyclo [4.3.

Abstract: Pharmaceutical dosage unit compositions containing, as a combination of active ingredients, dipyridamole and sulfinpyrazone, and a method of using the same as antithrombotics.

Abstract: A multiple-step process for the preparation of 6-aryl-4H-s-triazolo-[3,4-c]-thieno-[2,3-e]-1,4-diazepines of the formula ##STR1## wherein R.sub.1 is hydrogen, halogen or lower alkyl of 1 to 2 carbon atoms;R.sub.2 is hydrogen, chlorine, bromine, straight or branched alkyl of 1 to 3 carbon atoms, .omega.-hydroxyalkyl of 1 to 3 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or a 5- or 6-membered heterocycle comprising an oxygen sulfur or nitrogen atom, where the nitrogen atom may optionally be substituted by lower alkyl; andR.sub.3 is hydrogen, fluorine, chlorine, or bromine;and optionally acid addition salts thereof, starting from compounds of the formula ##STR2## wherein R.sub.1 and R.sub.3 have the meanings defined above, andX is halogen, amino or acyloxy.

Abstract: Therapeutic system in the form of a skin patch that administers clonidine transdermally in an initial priming dose of 10 to 300 mcg/cm.sup.2 of skin that brings the concentration of clonidine in the blood to a level sufficient to elicit alpha-adrenergic stimulation without intolerable side effects, followed by a substantially constant continuous dosage in the range of 0.1 to 100 mcg/hr that maintains said level. The system is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-clonidine reservoir lamina that is the source of the clonidine for the continuous constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-clonidine contact adhesive layer that is the source of the clonidine for the priming dose and the means by which the system is attached to the skin.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, chlorine, bromine or alkyl of 1 to 4 carbon atoms;R.sub.2 is hydrogen, fluorine, chlorine, bromine, nitro or trifluoromethyl; andR.sub.3 is chlorine, bromine, alkoxy of 1 to 3 carbon atoms, alkylmercapto of 1 to 3 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, cycloalkenyl of 3 to 6 carbon atoms, or a saturated or unsaturated 5- to 6-membered heterocycle comprising an oxygen, sulfur or nitrogen heteroatom, where a substitutable nitrogen heteroatom may optionally have a lower akyl substituent attached thereto;and non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as tranquilizers, muscle-relaxants and anticonvulsants.